<DOC>
	<DOCNO>NCT01302444</DOCNO>
	<brief_summary>Objectives : To test whether combined administration medication treprostinil ( prostacycline therapy ) , tadalafil ( PDE-5 [ phosphodiesterase type 5 ] Inhibitor therapy ) good administration treprostinil alone . This treatment would offer newly diagnose patient pulmonary arterial hypertension treatment disease deem candidate medication treprostinil physician . The combination therapy compare single therapy treprostinil double-blind manner . Current therapy begin one treatment , either PDE5 inhibitor prostacycline , depend severity patient 's PAH ( pulmonary arterial hypertension ) disease add additional therapy deterioration occur . This treatment could add two agent initially . Secondary objective : To improve pulmonary arterial pressure measure cardiac echocardiogram , improve subject 's 6minute walk distance , delay time clinical worsening , lower plasma BNP level . Research Procedures : To begin administration treatment time . Time period 16 week one- year follow-up . Cardiac Echocardiograms , clinic physician exam , lab work follow . Subjects age 18 - 75 .</brief_summary>
	<brief_title>Treprostinil Combined With Tadalafil Pulmonary Hypertension</brief_title>
	<detailed_description>Background : Many cardiovascular disease essential hypertension , coronary artery disease congestive heart failure respond well combination vasoactive drug , therapy single agent . Three category pulmonary anti-hypertensive medication develop last 20 year , effect management PAH use combination mostly unknown . Two pulmonary arterial hypertension ( PAH ) drug group prostacyclines , PDE5 inhibitor . Although effect prostacyclins mediate via cAMP ( cyclic guanosine monophosphate ) effect PDE5 inhibitor mediate via cGMP , considerable cross talk nucleotide suggest adequate level may need maintain normal pulmonary vascular tone cellular growth response . Objective/Hypothesis : This proposal hypothesize increase level nucleotide ( prostacyclines PDE5 inhibitor ) , may efficacious treatment PAH increase either one alone . Specific Aims : The primary objective study determine combination treprostinil infusion combine tadalafil efficacious treprostinil alone improve change baseline 6 minute walk distance 16 week therapy . Study Design : The propose study multi-center , randomize , double blind , two cohort , parallel group , 16-week study 1-year long-term follow-up . The study aim compare efficacy combination therapy treprostinil infusion tadalafil treprostinil infusion alone . Study Population : All patient newly diagnose PAH , consultation physician , elect treat treprostinil infusion invite participate . A total 66 subject sort enroll . Treprostinil dose follow 4 week up-titration schedule target 4week dose 8ng/kg/min minimum , follow 12 week randomize tadalafil period .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>1 . Adult patient 1880 year age 2 . World Health Organization Group 1 PAH 1 . Idiopathic PAH 2 . Heritable PAH 3 . PAH associate connective tissue disease 4 . PAH associate surgical repair congenital leave right shunt 5 . PAH associate anorectic drug use 3. WHO functional Class IIIIV 4 . 6 minute walk distance &gt; 150meters &lt; 450 meter 5 . Right heart catheterization show mean PAP ( pulmonary arterial pressure ) &gt; 25 mmHg PCWP ( pulmonary capillary wedge pressure ) &lt; 15 mmHg within 6 month study entry . 1 . Pulmonary hypertension associate a. Portal hypertension b. HIV infection c. Pulmonary venous hypertension define PCWP &gt; 15 mmHg d. Chronic lung disease define i. FEV1 ( forced expiratory volume one second ) /FVC ( forced vital capacity ) less 0.65 ii . TLC &lt; 0.70 iii . Untreated Sleep Apnea AHI ( apneahypopnea index ) &gt; 20 hemoglobin oxygen saturation nadir &lt; 87 % e. Chronic Thromboembolic Disease f. Sarcoidosis g. Pulmonary veno occlusive disease ( PVOD ) 2 . Concomitant use nitrate ( form ) either regularly intermittently . 3 . Concomitant use potent CYP3A inhibitor ( e.g. , ritonavir , ketoconazole , itraconazole ) 4 . Vascular disease retina include retinitis pigmentosa , sudden vision loss , include damage optic nerve NAION 5. low blood pressure high blood pressure control 6 . Postural hypotension 7 . Inability manage home infusion therapy 8 . Pulmonary vasodilator therapy phosphodiesterase inhibitor endothelin receptor antagonist within 30 day study entry 9 . Participation clinical investigational study within previous 30 day 10 . Renal failure define : 1. estimate creatinine clearance &lt; 30 ml/min 2. serum creatinine &gt; 2.5 mg/dl 11 . Subjects liver function abnormality ( ALT [ Alanine Aminotransferase AST ( Alanine Aminotransferase ) &gt; 3 time upper limit normal screen baseline ) chronic liver disease 12 . History hypersensitivity reaction adverse effect relate tadalafil 13 . Life expectancy &lt; 12 month 14 . History deform penis shape , erection last 4 hour , Peyronie 's disease . 15 . Blood cell problem sickle cell anemia , multiple myeloma , leukemia 16 . Pregnant plan become pregnant breast feed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>treprostinil</keyword>
	<keyword>pulmonary hypertension , tadalafil</keyword>
</DOC>